Kyverna Therapeutics filings document a late-stage clinical biopharmaceutical company developing cell therapies for autoimmune diseases. Its Form 8-K disclosures frequently cover Regulation FD updates for miv-cel clinical data, business and financial results, and material corporate events involving leadership, board composition, and commercial organization changes.
The company's proxy and governance filings describe director elections, board committees, executive compensation, stockholder voting matters, and equity incentive arrangements, including inducement awards. SEC records also identify Kyverna's Nasdaq-listed common stock and provide formal disclosure around its CAR T development strategy, clinical programs in neuroimmunology, capital planning, risk factors, and public-company governance.
Miller Andrew Craig reported acquisition or exercise transactions in this Form 4 filing.
Kyverna Therapeutics director Andrew Craig Miller reported equity awards consisting of a stock option for 42,945 shares and a restricted stock unit grant for 11,006 shares of common stock. The RSUs vest in three equal annual installments, while the option vests monthly over 36 months, in each case subject to continued service.
Kyverna Therapeutics director Emany Sravan Kumar received new equity awards. On February 24, 2026, Kumar was granted a stock option for 42,945 shares at an exercise price of $0.00 per share and 11,006 shares of common stock as a restricted stock unit award.
The restricted stock units are scheduled to vest in three equal annual installments on each one-year anniversary of the grant date, subject to continued service. The stock option is scheduled to vest in 36 equal monthly installments starting from the grant date, also conditioned on continued service to the company.
Kyverna Therapeutics, Inc. director Emany Sravan Kumar filed an initial ownership report on Form 3. The filing identifies Kumar as a director of Kyverna but does not list any transactions or report any share purchases, sales, acquisitions, or dispositions at this time.
Kyverna Therapeutics appointed two new independent directors as it refreshes its board. Andrew Miller, Ph.D., founder and former R&D president of Karuna Therapeutics, joins as a Class III director and member of the Audit and Science and Technology Committees. He will receive annual cash retainers for board and committee service and initial equity awards sized at $262,000 in stock options and $87,500 in restricted stock units, subject to service-based vesting and full vesting on a Change in Control.
Sravan Emany, CFO of Beam Therapeutics and former CFO/COO of Ironwood Pharmaceuticals, joins as a Class I director, Chair of the Audit Committee and member of the Nominating and Corporate Governance Committee, with similar cash and equity compensation levels and change-in-control vesting. Director Daniel Spiegelman resigned effective February 24, 2026, and the company states his resignation was not due to any disagreement with operations, policies or practices.
Kyverna Therapeutics, Inc. investors led by Northpond entities and Michael P. Rubin report their beneficial ownership in an amended Schedule 13G as of December 31, 2025. Michael P. Rubin is shown with beneficial ownership of 3,466,826 shares of common stock, representing 6.1% of the class.
The filing lists 2,805,426 shares (4.9%) held by Northpond Ventures III, LP, 450,000 shares (0.8%) held by Northpond Ventures, LP, and 211,400 shares (0.4%) held by NVP Listed, LLC, with shared voting and dispositive power over these positions. The percentages are based on 43,796,170 shares outstanding as of October 31, 2025 plus 13,333,333 shares issued in a December 18, 2025 public offering. The reporting persons certify the holdings are not for the purpose of changing or influencing control of Kyverna.
Bain Capital Life Sciences Opportunities III, LP reported a significant ownership stake in Kyverna Therapeutics, Inc. common stock. As of the close of business on December 31, 2025, the fund beneficially owned 3,110,000 shares, representing approximately 5.4% of Kyverna’s outstanding common stock.
The filing states that these shares are held with shared voting and dispositive power through a chain of Bain Capital Life Sciences entities organized in Delaware. The ownership percentage is based on 57,127,420 shares outstanding reported by Kyverna in a prospectus supplement filed on December 18, 2025.
The reporting person certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of Kyverna, but rather as a passive investment under the applicable beneficial ownership rules.
Kyverna Therapeutics, Inc. executive Mayobanex Pujols, the company’s Chief Technology Officer, filed an initial ownership report on Form 3. The filing states that no securities of Kyverna Therapeutics, Inc. are beneficially owned by the reporting person.
Kyverna Therapeutics’ Chief Technology Officer, Mayobanex Pujols, received a grant of stock options for 300,000 shares of common stock on February 9, 2026, with an exercise price of $8.08 per share. These options were acquired as a compensatory award and are held directly.
According to the vesting terms, one-fourth of the option shares vest on February 9, 2027. The remaining shares vest in 1/48th increments each month thereafter, contingent on Pujols’ continuous service with Kyverna through each vesting date. After this grant, he beneficially owns 300,000 derivative securities in the form of these options.
Kyverna Therapeutics, Inc. received an updated ownership report showing that funds affiliated with Westlake BioPartners and Dr. Beth C. Seidenberg beneficially own a significant minority stake in the company’s common stock.
Westlake BioPartners Fund I, L.P. reports beneficial ownership of 3,787,940 shares of Kyverna common stock, representing 6.3% of the class. Westlake BioPartners Opportunity Fund I, L.P. reports 869,317 shares, or 1.5% of the class. In total, Dr. Seidenberg is reported as beneficially owning 4,657,257 shares, or 7.8% of Kyverna’s common stock as of the December 31, 2025 event date.
The filing explains that these shares are held through Westlake limited partnerships, with their respective general partners and Dr. Seidenberg “may be deemed” to have sole voting and dispositive power, while all reporting persons disclaim beneficial ownership beyond their pecuniary interest. The amendment also notes that Dr. Sean E. Harper is no longer a managing director of the general partners and is therefore removed as a reporting person.
Kyverna Therapeutics, Inc. reported a leadership transition and a change to its inducement equity plan. Karen Walker notified the company on January 29, 2026 that she will retire and step down as Chief Technology Officer, effective February 9, 2026. The company noted that her resignation is not due to any disagreement regarding operations, policies, or practices.
On the same date, the board’s Compensation Committee amended and restated the 2024 Inducement Equity Incentive Plan to increase the shares of common stock available for grant by 1,000,000, bringing the aggregate to 5,000,000 shares. This change was adopted without stockholder approval under Nasdaq Listing Rule 5635(c)(4) and maintains the plan’s focus on equity awards used as material inducements for new or rehired employees. The company also announced the appointment of Mayo Pujols as Chief Technology Officer, effective February 9, 2026.